Commenting on the acquisition, LeMaitre Vascular president Dave Roberts said the Omniflow II vascular graft is a natural companion to XenoSure, which is bovine vascular patch.

"It has a proven track record with approximately 20,000 implants since 1990. This product should benefit from our vascular-only sales channel, particularly in Europe where Xenotis has used independent distributors."

Xenotis, which sold 95% of its products through distributors in its fiscal 2014, owns regulatory approvals in Europe, Australia, New Zealand, Canada and Brazil.

Xenotis produces Omniflow II in its facility in North Melbourne of Victoria, Australia.

As part of this transaction, LeMaitre acquired the Xenotis building with an appraised value of $1.9m.

LeMaitre develops, manufactures and markets disposable and implantable vascular devices.